When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis;Quand proposer une association d'hypolipémiants chez un patient non à l'objectif thérapeutique sous monothérapie? Recommandations de la NSFA

Archives des Maladies du Coeur et des Vaisseaux

Volumn 100, Issue 6-7, 2007, Pages 569-581

  Farnier, M ^a   Bonnet, F ^b   Bruckert, E ^c   Ferrières, Jean ^d   Paillard, F ^e  

^a Rond Point de la Nation ^*

^b EDOUARD HERRIOT HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d CHU RANGUEIL   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CIPROFIBRATE; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; LIVER DISEASE; LIVER TOXICITY; MEDICAL SOCIETY; MONOTHERAPY; MYOPATHY; NAUSEA; PANCREATITIS; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN ALLERGY; SKIN MANIFESTATION; STOMACH PAIN; TREATMENT FAILURE; TREATMENT INDICATION;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; CHOLESTYRAMINE; CLOFIBRIC ACID; DRUG COMBINATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; TREATMENT OUTCOME;

EID: 34547813216     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. AFSSAPS. Prise en charge thérapeutique du patient dyslipidémique. Recommandations mars 2005. www.agmed.sante.gouv.fr
2. Grundy SM, Cleeman JI, Merz CNB, et al. for the coordinating committee of the national cholesterol education program. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004 ; 110 : 227-39.
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke : systematic review and meta-analysis. BMJ 2003 ; 326 : 1423-9.
4. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP (Ezetimibe Study Group). Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolemia : a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003 ; 57 : 363-8.
5. Birjmohun RS Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds : a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005 ; 45 : 185-97.
6. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999 ; 341 : 498-511.
7. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL-cholesterol in hypercholesterolemic patients : the Ezetimibe add-on to statin effectiveness (EASE) trial. Mayo Clin Proc 2005 ; 80 : 587-95.
8. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and coleveselam in patients with primary hypercholesterolemia. Am J Med 2001 ; 110 : 352-60.
9. Hunninghake D, Insull W, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of coleveselam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001 ; 158 : 407-16.
10. Jacobson TA. Combination lipid-altering therapy : an emerging treatment paradigm for the 21 st century. Curr Atheroscler Rep 2001 ; 3 : 373-82.
11. Bays HE, Dujovne CA, Mc Govern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor versus other cholesterol-modulating agents trial evaluation [ADVOCATE]). Am J Cardiol 2003 ; 91 : 667-72.
12. Farnier M. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative. A critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs 2003 ; 3 : 169-78.
13. Grundy SM, Vega GL, Yuan Z, Bottisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005 ; 92 : 462-8.
14. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 ; 345 : 1583-92.
15. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 ; 110 : 3512-7.
16. Whitney EJ, Krasuski Ra ; Personius BE, et al. A randomised trial of a strategy for increasing high-density lipoprotein cholesterol levels : effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005 ; 142 : 95-104.
17. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005 ; 96 (Suppl) : 44K-49K.
18. Janz NK, Becker MH. The Health belief model: a decade later. Health Educ Q 1984 ; 11: 1-47.
19. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs : a lost opportunity. Pharmacotherapy 2001 ; 21 : 576-82.
20. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005 ; 165 : 1147-52.
21. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004 ; 22 Suppl 3: 13-23.
22. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA. Association between short-term effectiveness of statins and lonq-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005 ; 62 : 1468-75.
23. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002 ; 288 : 462-7.
24. Farnier M, Freeman MW, Macdonell G, et al. for the Ezetimibe study group efficacy and safety of the co-administration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. Eur Heart J 2005 ; 26 : 897-905.
25. Jelesoff NE, Ballantyne CM, Xydakis AM, et al. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract 2006 ; 12 : 159-64.
26. Penn R, Williams III RX, Guha-Ray DK, et al. An open-label, crossover study of the pharmacokinetics of insoluble drug delivery - microparticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Clin Ther 2006 ; 28 : 45-54.